Background-Plasma levels of atrial natriuretic peptide (ANP) are elevated in patients with chronic obstructive pulmonary disease (COPD) and may have a role in preventing oedema formation in these patients. Methods-Plasma ANP levels were measured in 60 patients with COPD and these measurements were related to pulmonary haemodynamics, response to treatment during exacerbations, and clinical patterns of the stable disease. Results-Plasma ANP levels did not correlate significantly with right atrial or pulmonary arterial pressures but did correlate significantly with both the right ventricular end diastolic volume and right ventricular wall volume measured by magnetic resonance imaging. Oxygen (2 1/min by nasal prongs for 30 minutes) did not change the mean pulmonary arterial pressure or the level of plasma ANP. In 20 patients with an acute exacerbation of COPD plasma ANP levels were higher in those with oedema (302 (185) pg/ml) than in those without oedema (87 (43) pg/ml). Oxygen given for one hour had no effect on plasma levels of ANP. However, plasma ANP levels fell over the first three days during treatment in those with oedema, the fall correlating with the change in body weight. In a further 20 stable patients with hypoxic COPD, those with hypercapnia and previous episodes of oedema had higher levels of plasma ANP (120 (50) pglml) than normocapnic patients with no previous oedema (54 (15) pg/ml). Conclusions-The level of ANP is high in the plasma of patients with COPD, particularly during exacerbations in those with oedema. The association of a high plasma ANP level and volume overload is shown by the fall in ANP levels with treatment of the oedema, and the correlation between levels of ANP and right ventricular end diastolic or wall volumes. (Thorax 1993;48:730-735) The traditional view of the development of peripheral oedema in patients with chronic obstructive pulmonary disease (COPD) suggests that chronic hypoxia is responsible for pulmonary vasoconstriction which eventually leads to irreversible pulmonary hypertension, increased right ventricular work, and right ventricular failure.' 2 This sequence of events has been challenged recently.3 The right ventricular performance is relatively well preserved in patients with COPD, even in the face of pulmonary hypertension.45 Moreover, the decline in right ventricular function in patients with COPD presenting with oedema may not be as a direct result of an augmented right ventricular afterload.5 6 Furthermore, not all patients with COPD and pulmonary hypertension develop oedema, suggesting decompensated cor pulmonale during exacerbations of their condition.
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Since de Bold et all' showed that human cardiocytes in both atria produce and store a potent natriuretic peptide-atrial natriuretic peptide (ANP)-this substance has been extensively studied in patients with congestive cardiac failure. In these patients plasma ANP levels correlate variably with the pulmonary arterial or right atrial pressures.'2-'1 The general view, however, is that atrial stretch is the major stimulus to the release of ANP.12 16 17 The role of ANP in the development of the clinical syndrome of cor pulmonale is unknown. Recent reports of measurement of ANP levels in patients with various chronic lung diseases including COPD have shown that these patients have higher levels of plasma ANP than normal subjects. [17] [18] [19] Preliminary studies also suggest that levels of ANP are even higher in those with decompensated cor pulmonale. Plasma Age (years) 67 (6) 70 (7) FEVy (1) 
Paco2 (kPa) (fig 3) . There was, however, a significant fall in ANP while breathing oxygen on day 2 (168 (132) pg/ml) and day 3 (158 (11) pg/ml) compared with the values on admission (256 (181) pg/ml, p < 0 05) for the whole group. The mean plasma ANP level was still significantly higher on day 3 in those with oedema (232 (46) pg/ml) than in those without oedema (88 (17) pg/ml, p < 0-05). Six weeks after the acute exacerbation, when the patients were clinically stable, the level of ANP in the plasma was unchanged in those who presented without oedema (87 (16) pg/ml) compared with the level on admission (87 (43) pg/ml, p > 0-05) but had fallen further in those who presented with oedema (118 (47) pg/ml; p < 0-05) (fig 3) . In the patients who had peripheral oedema at the time of admission the fall in body weight correlated with the fall in the level of plasma ANP (r = 0-85; p = 0 002) (fig 4) .
ANP IN THE DIFFERENT CINICAL PATTERNS OF COPD
Patients who were defined as having the "blue and bloated" syndrome of COPD had a lower FEVI, were more hypoxaemic, and were hypercapnic compared with those considered to be "pink puffers" (table 2) . The level of plasma ANP measured in those with the "blue and bloated" type of COPD was higher than in those with the "pink and puffing" type (table 2) although there was clearly some overlap between the groups ( fig 5) . Discussion ANP is an important humoral regulator of salt and water balance and of arterial pressure.'4 When given to healthy subjects it causes natriuresis, vasodilation, and can also suppress the activity of the renin-angiotensinaldosterone system,'8'9 actions which would be beneficial in cor pulmonale. Plasma ANP levels are elevated in patients with primary or secondary pulmonary hypertension'16 21 28 29 and correlate with both the mean pulmonary arterial (PPA) and right atrial pressures in some studies'720 but not in others.2' These conflicting data may arise because of the small number of patients studied and the narrow range of haemodynamic variables. Plasma ANP levels rise in response to the increase in PPA during exercise,28 presumably because of an increase in right atrial pressure and atrial distension. However, in a group of patients with primary pulmonary hypertension with raised PPA levels (mean PPA 74(13) mm Hg) plasma ANP levels were elevated in all but one patient despite normal right atrial pressures.29
Our study helps to resolve these conflicting data in a larger group of patients with a wide range of pulmonary arterial pressures. In this group we found no significant correlation between pulmonary arterial or right atrial pressure and simultaneously sampled plasma ANP levels. Furthermore, the levels of plasma ANP in patients with hypoxic COPD were similar in central venous and peripheral arterial blood, whereas others have found higher levels of ANP in central than in peripheral blood.'7 Since atrial stretch is thought to be the major stimulus to the release of ANP it is not surprising that central venous pressure measurements, which are a poor reflection of atrial stretch, do not correlate well with the levels of ANP. Surprisingly, in previous studies the correlation between plasma ANP levels and right atrial pressure was present even when the atrial pressure remained within the normal range,'7 although this relationship was not confirmed in other studies.2'
Although we were not able to make direct measurements of atrial chamber size, we found a significant relationship between right ventricular end diastolic chamber volume and right ventricular wall volume, measured by MRI, and plasma ANP levels. We presume that an increase in right ventricular volume would also be associated with an increased atrial volume and presumably atrial stretch.'0 The correlation between ANP levels and right ventricular wall volume is interesting since in animal studies hypoxia is associated with both increased right ventricular mass and, in addition, an increase in messenger RNA expression for ANP in the right ventricular wall."
These data confirm the presence of elevated levels of plasma ANP in 60 patients with COPD. Although plasma ANP levels were higher in patients with an exacerbation of COPD than in normal subjects, very high levels (>120 pg/ml) occurred only in those with oedema. This finding did not relate to the severity of the disease. Previous studies suggest that, during an exacerbation of COPD, pulmonary arterial pressure rises32 which presumably would cause release of ANP as a result of increased atrial stretch. An increase in central blood volume secondary to activation of the renin-angiotensinaldosterone system and consequent salt and water retention33 could also increase atrial stretch and ANP release. High levels of ANP should have a protective role in the development of oedema in patients with COPD and hypoxia due to its beneficial haemodynamic effects and the inhibitory effects of ANP on the renin-angiotensin system.'4 Furthermore, the release of ANP remains responsive to physiological manipulations in patients with COPD.3" However, why sodium and water retention still occurs in patients with hypoxic COPD and oedema in the face of very high levels of plasma ANP remains unclear. Several explanations are possible such as a blunted renal response to ANP36 or the possibility that the suppressive effect of ANP on the renin-angiotensin axis is outweighed by the stimulatory effect of inadequate renal perfusion'7 on the renin-angiotensin system. '8 Since the level of hypoxaemia was not different in patients with exacerbations of COPD with and without oedema, both groups would presumably have pulmonary hypertension at least acutely.'2 However, the degree of hypercapnia and acidosis was higher in those with oedema, as noted in a previous study,39 and may have contributed to a further increase in pulmonary arterial pressure, stimulation of the renin-angiotensin system, reduction of effective renal plasma flow, and thus the filtered sodium load. 40 The fall in plasma ANP levels with treatment in patients with oedema is likely to be due to a combination of factors including the improvement in blood gas values, a fall in pulmonary arterial hypertension,32 and reduction in central venous pressure consequent on a diuresis. Support for this latter mechanism comes from the relationship between the fall in body weight and the fall in ANP levels in these patients.
The pathogenesis of the oedema in cor pulmonale remains unknown.6 The adaptive mechanisms which occur in response to chronic pulmonary hypertension, such as an increase in right ventricular end diastolic volume,' may also produce a chronic elevation of ANP levels. This hypothesis is supported by the presence of elevated ANP levels in those patients who had hypercapnia and a past history of peripheral oedema compared with those who were normocapnic and had never had oedema. An increased level of ANP consequent upon the higher levels of pulmonary arterial pressure in the "blue bloaters" may be one of the reasons why oedema does not always develop in patients with COPD and pulmonary hypertension, even during exacerbations.532
Our data show that oxygen given acutely to hypoxic patients, whether in a stable state or during an exacerbation, has no effect on ANP levels. These findings confirm those of other workers in studies of patients with stable COPD.21 Furthermore, short term discontinuation of oxygen does not appear to affect the levels of ANP in patients with hypoxic COPD treated with long term oxygen therapy. 27 The effect of long term oxygen therapy on plasma ANP levels has not been studied, although oxygen given over six days to hypoxic patients with COPD did not alter the level of ANP in the plasma. 28 The results of this study suggest that the complex interactions between pulmonary haemodynamics, blood gas values, the reninangiotensin system, and ANP in patients with exacerbations of COPD with and without oedema are worthy of further study, since they may lead to more logical treatment of patients with exacerbations of COPD and oedema.
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